Herpes zoster and postherpetic neuralgia in older adults
- PMID: 17631237
- PMCID: PMC4859150
- DOI: 10.1016/j.cger.2007.03.003
Herpes zoster and postherpetic neuralgia in older adults
Abstract
Herpes zoster (HZ) afflicts millions of older adults annually and causes significant suffering from acute and chronic pain, or postherpetic neuralgia (PHN). HZ is caused by the reactivation of varicella-zoster virus (VZV) in sensory ganglia in the setting of age, disease, and drug-related decline in cellular immunity. VZV-induced neuronal destruction and inflammation cause the pain, interference with activities of daily living, and reduced quality of life. The optimal treatment of HZ requires early antiviral therapy and pain management. For PHN, evidence-based pharmacotherapy can reduce pain burden. The zoster vaccine is effective in reducing pain burden and preventing HZ and PHN in older adults.
References
-
- Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–1349. - PubMed
-
- Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. - PubMed
-
- Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:RR–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical